Telectronics replacements for withdrawn Encor/Accufix pacer leads pending at FDA.
This article was originally published in The Gray Sheet
Executive SummaryTELECTRONICS REPLACEMENTS FOR ENCOR/ACCUFIX PACER LEADS are undergoing premarket review by FDA, the firm states. Two Maxim passive fixation (non-steroidal) atrial leads - one unipolar and one bipolar -- have been under 510(k) review by the agency since the applications were submitted in the first quarter, Telectronics says. A 510(k) also is pending for the firm's Secure active fixation (non-steroidal), bipolar, ventricular lead.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.